Conditions that significantly enhance the proportion of cells with CD34+ thy-1+ phenotype in the cultures
| Treatments . | Frequency of CD34+ thy-1+– Positive Wells . | Percentage of CD34+ thy-1+Cells . |
|---|---|---|
| None | 100% (20/20) | 9 ± 2 |
| IL-3+IL-6+SCF | 100% (20/20) | 14 ± 2 |
| IL-3+IL-6+SCF+FL | 100% (20/20) | 17 ± 3 |
| GM-CSF+IL-3+IL-6+SCF | 100% (20/20) | 18 ± 4 |
| GM-CSF+IL-3+IL-6+SCF+FL | 100% (20/20) | 18 ± 4 |
| TPO+SCF | 100% (20/20) | 14 ± 2 |
| TPO+FL+SCF | 100% (20/20) | 16 ± 2 |
| TPO+FL+SCF+IL-3 | 100% (20/20) | 18 ± 4 |
| TPO+FL+SCF+IL-6 | 100% (20/20) | 18 ± 3 |
| TPO+FL+SCF+IL-3+IL-6 | 100% (20/20) | 20 ± 4 |
| Treatments . | Frequency of CD34+ thy-1+– Positive Wells . | Percentage of CD34+ thy-1+Cells . |
|---|---|---|
| None | 100% (20/20) | 9 ± 2 |
| IL-3+IL-6+SCF | 100% (20/20) | 14 ± 2 |
| IL-3+IL-6+SCF+FL | 100% (20/20) | 17 ± 3 |
| GM-CSF+IL-3+IL-6+SCF | 100% (20/20) | 18 ± 4 |
| GM-CSF+IL-3+IL-6+SCF+FL | 100% (20/20) | 18 ± 4 |
| TPO+SCF | 100% (20/20) | 14 ± 2 |
| TPO+FL+SCF | 100% (20/20) | 16 ± 2 |
| TPO+FL+SCF+IL-3 | 100% (20/20) | 18 ± 4 |
| TPO+FL+SCF+IL-6 | 100% (20/20) | 18 ± 3 |
| TPO+FL+SCF+IL-3+IL-6 | 100% (20/20) | 20 ± 4 |
All treatments were performed in 200% SCM-LIF. Cells from individual wells were analyzed by flow cytometry after 3 weeks in culture. See Table 1 for additional information.